Maze Therapeutics (NASDAQ:MAZE) Insider Sells $240,525.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $32.07, for a total transaction of $240,525.00. Following the sale, the insider owned 32,316 shares of the company’s stock, valued at $1,036,374.12. This represents a 18.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Tuesday, September 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.06, for a total value of $202,950.00.
• On Thursday, September 3rd, Atul Dandekar sold 3,243 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total transaction of $84,350.43.
• On Wednesday, September 2nd, Atul Dandekar sold 3,191 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total value of $84,465.77.
• On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00.

Maze Therapeutics Stock Down 1.4%

Shares of NASDAQ:MAZE traded down $0.45 on Friday, hitting $31.48. 326,504 shares of the company traded hands, compared to its average volume of 676,789. Maze Therapeutics, Inc. has a 52 week low of $21.95 and a 52 week high of $53.65. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $27.44 and a 200-day simple moving average of $32.04. The company has a market cap of $1.75 billion, a PE ratio of -12.49 and a beta of 2.16.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.76). As a group, research analysts expect that Maze Therapeutics, Inc. will post -2.70 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Monday, September 21st. Canaccord Genuity Group assumed coverage on Maze Therapeutics in a report on Monday, October 19th. They set a “buy” rating and a $75.00 price target for the company. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Tuesday, September 22nd. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Wedbush reaffirmed an “outperform” rating and set a $48.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. Three analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $64.45.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of MAZE. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Maze Therapeutics during the third quarter valued at approximately $77,000. Profund Advisors LLC boosted its position in shares of Maze Therapeutics by 410.5% during the third quarter. Profund Advisors LLC now owns 56,281 shares of the company’s stock worth $1,530,000 after acquiring an additional 45,256 shares during the last quarter. Sterling Capital Management LLC boosted its position in shares of Maze Therapeutics by 390.5% during the third quarter. Sterling Capital Management LLC now owns 1,089 shares of the company’s stock worth $30,000 after acquiring an additional 867 shares during the last quarter. Squarepoint Ops LLC grew its stake in Maze Therapeutics by 42.8% during the second quarter. Squarepoint Ops LLC now owns 19,434 shares of the company’s stock valued at $580,000 after acquiring an additional 5,822 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. grew its stake in Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after acquiring an additional 465,641 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions.

Maze’s pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease.